Johnson & Johnson (NYSE:JNJ) Shares Sold by High Net Worth Advisory Group LLC

High Net Worth Advisory Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 3.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,663 shares of the company’s stock after selling 298 shares during the period. High Net Worth Advisory Group LLC’s holdings in Johnson & Johnson were worth $1,566,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Pineridge Advisors LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth $193,000. Transcendent Capital Group LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $185,000. Creekmur Asset Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $709,000. Royal London Asset Management Ltd. boosted its holdings in Johnson & Johnson by 3.4% in the 4th quarter. Royal London Asset Management Ltd. now owns 1,619,599 shares of the company’s stock worth $253,856,000 after acquiring an additional 53,116 shares during the period. Finally, Northwest Bank & Trust Co acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $223,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

Shares of NYSE JNJ opened at $161.46 on Monday. The company has a market cap of $388.58 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The stock’s 50 day simple moving average is $162.59 and its 200 day simple moving average is $154.46. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.07%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Royal Bank of Canada raised their price objective on Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.